Hilleman Laboratories advances two vaccines into clinical stage

Initiates clinical trials for heat-stable Rotavirus vaccine and next-generation Cholera vaccine


The firm aims to boost GAVI and Government of India’s universal immunization programs with heat-stable and affordable Rotavirus vaccine for improved coverage

Advancing closer to its vision of bridging the vaccination gap in developing nations, Hilleman Laboratories, a first-of-its-kind joint-venture between Merck Sharp & Dohme (MSD) and the Wellcome Trust, has announced the initiation of Phase I/II clinical trial of its innovative vaccine, an oral, lyophilized, heat-stable Rotavirus vaccine, against Rotavirus disease.

After successful completion of the preclinical stage and obtaining regulatory clearance, Hilleman Laboratories has initiated a clinical study to establish proof-of-concept for its heat stable Rotavirus vaccine candidate.

Hilleman Laboratories also obtained regulatory clearance for its innovative oral Cholera vaccine to conduct a Phase I/II clinical study that is intended to lead to an affordable vaccine against devastating Cholera infection.

Commenting on these developments, Dr Davinder Gill, CEO, Hilleman Laboratories said, "These are exciting times at Hilleman Laboratories with several of our initiatives moving closer to meeting their objectives. There is a real need for safer and more effective vaccines to address the unmet needs of low-income nations. We have designed both Rotavirus and Cholera vaccine candidates keeping in view the socio-economic and demographic needs of developing nations. While on one hand, our heat-stable technology will offer longer stability to the Rotavirus vaccine in extreme climates, the next-generation oral Cholera vaccine will be affordable and easy-to-administer."

Dr Gerd Zettlmeissl, Chairman of Board of Directors, Hilleman Laboratories said, "I congratulate the entire team at the Hilleman Laboratories on achieving this significant milestone. These developments further strengthen my belief in our vision of saving millions of lives lost due to preventable diseases in low income settings." In light of the World Immunization Week themed ‘Close the Immunization Gap' by WHO, the new developments gives a massive impetus to the company's commitment towards realizing this goal.


Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email